Biomarkers for Diabetic Kidney Disease: Researchers Investigate Autologous Dendritic Cell Transfer

Strategic Insights -

Researchers from Universitas Prima Indonesia have published a new study examining the therapeutic impact of autologous dendritic cell transfer on diabetic kidney disease (DKD). The study aimed to evaluate the effects of this treatment on renal microstructural changes and key inflammatory biomarkers. A clinical trial was conducted with 25 DKD patients receiving outpatient care at Gatot Soebroto Army Hospital, where each participant was administered a single injection of autologous dendritic cells. Evaluations were conducted prior to and one month following the treatment, with notable increases in Diffusion Tensor Imaging (DTI) MRI-derived Fractional Anisotropy (FA) scans, but no significant changes in inflammatory biomarkers Matrix Metalloproteinase-9 (MMP-9) and Intercellular Adhesion Molecule-1 (ICAM-1). The research concluded that the transfer of autologous dendritic cells significantly enhanced FA, which correlates with a reduction in the inflammatory biomarker MMP-9, suggesting a potential impact on renal repair in DKD.

Key Takeaways:

  • The study aimed to evaluate the therapeutic impact of autologous dendritic cell transfer on diabetic kidney disease (DKD) patients.
  • A clinical trial was conducted with 25 DKD patients, who received a single injection of autologous dendritic cells.
  • Evaluations were conducted prior to and one month following the treatment, with notable increases in FA scans.
  • No significant changes were observed in inflammatory biomarkers MMP-9 and ICAM-1 levels.
  • A negative correlation was found between FA and MMP-9 (r = -0.324, * * p* * = 0.025).
  • The research concluded that the transfer of autologous dendritic cells may have a potential impact on renal repair in DKD.

Patients and Methods:

  • 25 DKD patients were enrolled in a clinical trial at Gatot Soebroto Army Hospital.
  • Each participant received a single injection of autologous dendritic cells.
  • Evaluations were conducted prior to and one month following the treatment.
  • The primary measurements included DTI MRI-derived FA scans and the inflammatory biomarker MMP-9.

Statistics:

  • The number of DKD patients enrolled in the clinical trial was 25.
  • The single injection of autologous dendritic cells was administered to each of the 25 participants.
  • The evaluations conducted prior to and one month following the treatment showed notable increases in FA scans, with a rise from 242.57 ± 63.97 at baseline to 305.61 ± 152.32 one month after the dendritic cell injection.

Sources:

  • NewsRx. Data on Biomarkers Published by Researchers at Universitas Prima Indonesia (Diffusion Tensor Imaging Magnetic Resonance Imaging Assessment in a Clinical Trial of Autologous Dendritic Cell Transfer for Diabetic Kidney Disease: A Molecular Approach). Health & Medicine Week. June 13, 2025; p 68.
  • Diffusion Tensor Imaging Magnetic Resonance Imaging Assessment in a Clinical Trial of Autologous Dendritic Cell Transfer for Diabetic Kidney Disease: A Molecular Approach. Diseases, 2025,13(5):159. (Diseases - http://www.mdpi.com/journal/diseases). The publisher for Diseases is MDPI AG.